© COPYRIGHT 2023 IMAGEN THERAPEUTICS LTD.
Company Registered in England & Wales No. 06373341
Amplification or overexpression of HER2 occurs in approximately 15–30% of breast cancers and 10–30% of gastric/gastroesophageal cancers and serves as a prognostic and predictive biomarker. HER2 overexpression has also been seen in other cancer types like ovary, endometrium, bladder, lung, colon, and head and neck. The introduction of HER2 targeted therapies has dramatically influenced the outcome of patients with HER2 positive breast and gastric/gastroesophageal cancers; however, the results have been proved disappointing in other HER2 overexpressing cancers.
Advanced in vitro cancer models that preserve patient HER2 mutation and aberrant expression are needed to translate preclinical findings into successuful new therapeutic approaches.
Choose up to 50 PDC models to enroll in our pan-cancer screen
Discover what Imagen can do for your drug development program, at any stage
Find out how PDC model can be applied as a tool for drug discovery and development
|Model ID||Cancer type||HER2 status (mutation, CNV, RNAseq*)||Patient treatment data|
|PTX-0118||Esophageal||WT, CNV=2, 63.3%||Contact us to see all model data|
|PTX-0053||Breast, HER2+||WT, CNV=2, 21%|
|PTX-0054||Breast, HER2+||WT, CNV=10, 99.6%|
|PTX-0074||Endometrial||WT, CNV=2, 71.8%|
|PTX-0100||Ovarian||WT, CNV=2, 66.1%|
|PTX-0114||Breast, HER2+/ER+/PR+||WT, CNV=2, 95.2%|
|PTX-0118||Breast, ER+/PR+||L755S mut, CNV=3, 100%|
|PTX-0137||Breast, HER2+||WT, CNV=2, N/A|
|PTX-0138||Breast, HER2+/ER+/PR+||WT, CNV=2, N/A|
|PTX-0139||Breast, HER2+/ER+||WT, CNV=2, 36.6%|
|PTX-0155||Breast, ER+||WT, CNV=2, 96.8%|
|PTX-0206||Breast, HER2+, ER+||NGS Pending|
|PTX-0275||Dermatofibrosarcoma||WT, CNV=2, 14.7%|
|PTX-0306||Breast, HER2+/ER+/PR+||WT, CNV=2, 97.1%|
|PTX-0446||Breast, HER2+/ER+/PR+||NGS Pending|
*(CNV: Copy Number Variation; RNAseq: expression percentile vs other models in the biobank)